National Heart, Lung, and Blood Institute; Notice of Closed Meeting, 24481 [2024-07376]
Download as PDF
<![CDATA[
Federal Register / Vol. 89, No. 68 / Monday, April 8, 2024 / Notices
lotter on DSK11XQN23PROD with NOTICES1
FOR FURTHER INFORMATION CONTACT:
William Parham at (410) 786–4669.
SUPPLEMENTARY INFORMATION: Under the
Paperwork Reduction Act of 1995 (PRA)
(44 U.S.C. 3501–3520), Federal agencies
must obtain approval from the Office of
Management and Budget (OMB) for each
collection of information they conduct
or sponsor. The term ‘‘collection of
information’’ is defined in 44 U.S.C.
3502(3) and 5 CFR 1320.3(c) and
includes agency requests or
requirements that members of the public
submit reports, keep records, or provide
information to a third party. Section
3506(c)(2)(A) of the PRA (44 U.S.C.
3506(c)(2)(A)) requires Federal agencies
to publish a 30-day notice in the
Federal Register concerning each
proposed collection of information,
including each proposed extension or
reinstatement of an existing collection
of information, before submitting the
collection to OMB for approval. To
comply with this requirement, CMS is
publishing this notice that summarizes
the following proposed collection(s) of
information for public comment:
1. Type of Information Collection
Request: New collection (Request for a
new OMB control number); Title of
Information Collection: The Medicare
Advantage and Prescription Drug
Programs: Part C and Part D Medicare
Advantage Prescription Drug (MARx)
System Updates for the Medicare
Prescription Payment Plan Program;
Use: The IRA amended the Act by
adding section 1860D–2(b)(2)(E) which,
beginning January 1, 2025, establishes
the Medicare Prescription Payment Plan
program (hereinafter referred to as the
‘‘program’’). Under this program, MA
Organizations offering Part D coverage
and Part D sponsors (collectively ‘‘Part
D plans’’ or ‘‘Plans’’) are required to
offer enrollees the option to pay their
Part D cost sharing in monthly amounts
spread out over the plan year based on
the formulae described in section
1860D–2(b)(2)(E)(iv) of the Act.
To effectively monitor the program,
Part D plans will be required to report
data elements related to the program at
the beneficiary, contract, and Plan
Benefit Package (PBP)1 levels beginning
in Contract Year (CY) 2025. In this
information collection package, CMS
addresses the proposal to require Part D
plans to submit beneficiary-level data
elements into the MARx system via a
program-specific transaction (separate
from the enrollment file). In accordance
with the Plan Communication User
Guide (PCUG), plans may submit
multiple transaction files during any
CMS business day, Monday through
Friday. Plan transactions are processed
VerDate Sep<11>2014
16:37 Apr 05, 2024
Jkt 262001
as received; there is no minimum or
maximum limit to the number of files
that Plans may submit in a day. In
general, transaction and processing
occur throughout the Current Calendar
Month (CCM). For CY 2025, CMS will
not require independent data validation
for this new MARx reporting
requirement. Form Number: CMS–
10887 (OMB control number: 0938–
New); Frequency: Monthly; Affected
Public: Private, Federal Government,
Business or other for profits, Not-forprofits institutions; Number of
Respondents: 856; Total Annual
Responses: 3,200,856; Total Annual
Hours: 59,958. (For policy questions
regarding this collection contact
Michael Brown at (872) 287–1370 or
michael.brown3@cms.hhs.gov.)
2. Type of Information Collection
Request: Revision with change of a
currently approved collection; Title of
Information Collection: Application to
be a Qualified Entity to Receive
Medicare Data for Performance
Measurement/Reapplication/Annual
Report Worksheet; Use: The Patient
Protection and Affordable Care Act
(ACA) was enacted on March 23, 2010
(Pub. L. 111–148). ACA amends section
1874 of the Social Security Act by
adding a new subsection (e) to make
standardized extracts of Medicare
claims data under Parts A, B, and D
available to QEs to evaluate the
performance of providers of services
and suppliers. This is the Application,
Reapplication, and ARW which
provides CMS with the information it
needs to determine whether an
organization earns approval and
continues as a QE.
CMS established the Qualified Entity
Certification Program (QECP) to
evaluate an organization’s eligibility
across three areas: (1) organizational and
governance capabilities, (2) addition of
claims data from other sources (as
required in the statute), and (3) data
privacy and security. QE certification
lasts for 3 years. Organizations that are
interested in remaining in the QE
program must submit a Reapplication
that is reviewed and approved by QECP.
In addition, each year QEs must submit
an annual report to QECP that provides
information required by statute. Form
Number: CMS–10394 (OMB control
number: 0938–1144); Frequency: Yearly;
Affected Public: Business or other forprofits; Number of Respondents: 40;
Total Annual Responses: 210; Total
Annual Hours: 17,400. (For policy
questions regarding this collection
PO 00000
Frm 00059
Fmt 4703
Sfmt 9990
24481
contact Kari Gaare at kari.gaare@
cms.hhs.gov.)
William N. Parham, III,
Director, Division of Information Collections
and Regulatory Impacts, Office of Strategic
Operations and Regulatory Affairs.
[FR Doc. 2024–07429 Filed 4–5–24; 8:45 am]
BILLING CODE 4120–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Heart, Lung, and Blood
Institute; Notice of Closed Meeting
Pursuant to section 1009 of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Heart, Lung,
and Blood Institute Special Emphasis Panel;
Genetics and Biology of von Willebrand
Disease.
Date: May 8, 2024.
Time: 1:00 p.m. to 4:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Rockledge II, 6701 Rockledge Drive,
Bethesda, MD 20892 (Virtual Meeting).
Contact Person: Manoj Kumar
Valiyaveettil, Ph.D., Scientific Review
Officer, Office of Scientific Review/DERA,
National Heart, Lung, and Blood Institute,
National Institutes of Health, 6705 Rockledge
Drive, Room 208–R, Bethesda, MD 20817,
(301) 402–1616, manoj.valiyaveettil@nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.233, National Center for
Sleep Disorders Research; 93.837, Heart and
Vascular Diseases Research; 93.838, Lung
Diseases Research; 93.839, Blood Diseases
and Resources Research, National Institutes
of Health, HHS)
Dated: April 3, 2024.
Melanie J. Pantoja,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2024–07376 Filed 4–5–24; 8:45 am]
BILLING CODE 4140–01–P
E:\FR\FM\08APN1.SGM
08APN1
]]>Agencies
[Federal Register Volume 89, Number 68 (Monday, April 8, 2024)]
[Notices]
[Page 24481]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2024-07376]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
National Heart, Lung, and Blood Institute; Notice of Closed
Meeting
Pursuant to section 1009 of the Federal Advisory Committee Act, as
amended, notice is hereby given of the following meeting.
The meeting will be closed to the public in accordance with the
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5
U.S.C., as amended. The grant applications and the discussions could
disclose confidential trade secrets or commercial property such as
patentable material, and personal information concerning individuals
associated with the grant applications, the disclosure of which would
constitute a clearly unwarranted invasion of personal privacy.
Name of Committee: National Heart, Lung, and Blood Institute
Special Emphasis Panel; Genetics and Biology of von Willebrand
Disease.
Date: May 8, 2024.
Time: 1:00 p.m. to 4:00 p.m.
Agenda: To review and evaluate grant applications.
Place: National Institutes of Health, Rockledge II, 6701
Rockledge Drive, Bethesda, MD 20892 (Virtual Meeting).
Contact Person: Manoj Kumar Valiyaveettil, Ph.D., Scientific
Review Officer, Office of Scientific Review/DERA, National Heart,
Lung, and Blood Institute, National Institutes of Health, 6705
Rockledge Drive, Room 208-R, Bethesda, MD 20817, (301) 402-1616,
[email protected].
(Catalogue of Federal Domestic Assistance Program Nos. 93.233,
National Center for Sleep Disorders Research; 93.837, Heart and
Vascular Diseases Research; 93.838, Lung Diseases Research; 93.839,
Blood Diseases and Resources Research, National Institutes of
Health, HHS)
Dated: April 3, 2024.
Melanie J. Pantoja,
Program Analyst, Office of Federal Advisory Committee Policy.
[FR Doc. 2024-07376 Filed 4-5-24; 8:45 am]
BILLING CODE 4140-01-P
